☆ 4.3 Editorial Material

Is Treatment for Cytopenic Myelofibrosis Still an Unmet Clinical Need?

HEMASPHERE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

Jean-Jacques Kiladjian et al.

Summary: Momelotinib has demonstrated benefits in symptoms, spleen, and anemia in patients with intermediate- and high-risk myelofibrosis (MF). It also shows comparable efficacy and safety in patients with MF and thrombocytopenia, suggesting it as a viable treatment option.

HEMASPHERE (2023)

添加到收藏夹

Article Hematology

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study

Ruben A. Mesa et al.

Summary: Research shows that momelotinib has significant symptom improvement effects for patients with myelofibrosis, and it also has positive efficacy for anemic patients. Compared to danazol, momelotinib has more pronounced improvements in fatigue and physical functioning.

HEMASPHERE (2023)

添加到收藏夹

Article Hematology

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

Jean-Jacques Kiladjian et al.

Summary: Momelotinib is a safe and effective treatment option for patients with MF and moderate-to-severe thrombocytopenia, providing benefits in symptoms, spleen, and anemia.

HEMASPHERE (2023)

添加到收藏夹

Article Hematology

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study

Ruben A. Mesa et al.

Summary: The study demonstrates that momelotinib provides substantial and durable symptom benefit for patients with myelofibrosis, especially in terms of fatigue and physical functioning.

HEMASPHERE (2023)

添加到收藏夹

Letter Hematology

Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib

Amy Zhou et al.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Meeting Abstract Hematology

Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis

Stephen T. Oh et al.

BLOOD (2022)

添加到收藏夹

Article Hematology

Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management

Ayalew Tefferi

Summary: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by stem cell-derived clonal myeloproliferation, with common features including bone marrow fibrosis, abnormal inflammatory cytokine expression, anemia, hepatosplenomegaly, etc. Diagnosis is primarily based on bone marrow morphology. Treatment strategies can vary based on risk stratification, with options such as observation, drug therapy, or hematopoietic stem cell transplant.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Review Hematology

Management of myelofibrosis after ruxolitinib failure

Claire N. Harrison et al.

ANNALS OF HEMATOLOGY (2020)

添加到收藏夹

Article Hematology

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Claire N. Harrison et al.

LANCET HAEMATOLOGY (2018)

添加到收藏夹

Letter Hematology

Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia

Juan-Carlos Hernandez-Boluda et al.

BRITISH JOURNAL OF HAEMATOLOGY (2018)

添加到收藏夹

Article Oncology

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis

Ruben A. Mesa et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs

Allison H. Scotch et al.

LEUKEMIA RESEARCH (2017)

添加到收藏夹

Article Hematology

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

Kate J. Newberry et al.

BLOOD (2017)

添加到收藏夹

Article Oncology

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

C. N. Harrison et al.

LEUKEMIA (2016)

添加到收藏夹

Article Medicine, General & Internal

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srdan Verstovsek et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Hematology

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Francesco Passamonti et al.

BLOOD (2010)

添加到收藏夹

Article Hematology

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

Francisco Cervantes et al.

BLOOD (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.